**Table S2 Patient characteristics**

|  |  |
| --- | --- |
| Features | N (20) |
| **Age** | 46-79 years (mean, 66; median, 67) |
| **Sex** MaleFemale | 137 |
| **PS** 0-12-3 | 200 |
| **Histology** IntestinalDiffuse | 119 |
| ***ERBB2***Not amplified Amplified Unknown | 1523 |
| ***TP53***Wild-type MutatedUnknown | 7103 |
| **MMR status** Proficient Deficient | 200 |
| **EBV infection** No Yes | 191 |
| **Treatment line** 2nd line3rd line- | 146 |
| **Regimen** RAM monotherapyRAM+PTX or nabPTXRAM+CPT-11 | 3125 |
| **Response** PRSDPD | 6113 |
| **Biopsy times** | 2-6 (mean, 3.25; median, 3) |
| **Median PFS**  | 110 days |
| **Median OS** | 324 days |

RAM, ramucirumab; PTX, paclitaxel; CPT-11, irinotecan; PFS, progression-free survival; OS, overall survival